인사이드, 파이낸스, 인더스트리, 엔터미디어 등 관련기사 제공

HYBE Announces Merger with Web3 Subsidiary Binary Korea: Kim Jisun 2025.04.01

LS Group's Essex Solutions to Expand Production Capacity in North America and Europe by 2030: Kim Jisun 2025.04.01

GS E&C Subsidiary Energy Materials to Lift Partial Lockout: Kim Jisun 2025.04.01

Hahn & Company Finalizes KRW 2.6 Trillion Acquisition of SK Specialty from SK Group: Kim Jisun 2025.04.01

SK Hynix Designated as Short-Selling Restricted Stock Amid Market Volatility: Kim Jisun 2025.04.01

France Fines Apple Over KRW 2 Trillion for Abuse of Market Dominance on App Store: Kim Jisun 2025.04.01

Yanolja CEO Lee Su-jin Donates 100 Shares of Company Stock to Global Employees: Kim Jisun 2025.03.31

Lotte Chemical Sells 4.9% Stake in Resona, Securing Additional Liquidity: Kim Jisun 2025.03.31

SC Bank Loses Final Appeal in 40 Billion Won Claim Lawsuit with Korea Line Corporation: Kim Jisun 2025.03.31

SpaceX’s Starlink Set to Launch Satellite Internet Service in South Korea: Kim Jisun 2025.03.31

SoftBank Plans AI-Powered Industrial Parks Across the U.S.: Kim Jisun 2025.03.31

Krafton Acquires Indian Cricket Game Developer Nautilus Mobile for $13.75 Million: Kim Jisun 2025.03.31

Luxury E-Commerce Platform Balaan Halts Payment Services Amid Settlement Controversy: Kim Jisun 2025.03.31

Samsung C&T Selected as Contractor for Shinbanpo 4th Reconstruction Project: Kim Jisun 2025.03.31

Financial Authorities Halt Hanwha Aerospace's $2.7 Billion Rights Offering, Citing Insufficient Justification: Kim Jisun 2025.03.28

Korea Investment Holdings to Pursue Insurance Company Acquisition: Kim Jisun 2025.03.28

Hoban Construction to Consider Appeal to Supreme Court Following Partial Cancellation of Fair Trade Commission's Fine: Kim Jisun 2025.03.28

SK Hynix to Finalize 2025 HBM Supply Deals with Nvidia and Major Clients by Mid-Year: Kim Jisun 2025.03.28

JW Pharmaceutical and CEO Indicted for Tax Evasion Over Rebate Expenses: Kim Jisun 2025.03.28

HanAll Biopharma Files Counterclaim in ICC Arbitration to Terminate HL161 License Agreement with Harbour BioMed in China: Kim Jisun 2025.03.28